Compare Novartis AG (NVS) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Prospect Capital Corporation — how do they compare? Novartis AG trades at $138.17 (market cap $262.64B), while Prospect Capital Corporation trades at $2.19 (market cap $1.13B). The key difference: Novartis AG is far larger — about 232.4× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (19.09%). Which is the better fit depends on your goals.
| NVS | PSEC | |
|---|---|---|
Market Cap | $262.64B | $1.13B |
Sector | Health | Financials |
52-Week High | $168.62 | $3.05 |
52-Week Low | $121.80 | $2.11 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | 19.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Prospect Capital (PSEC) trades at $2.19, down 1.79% recently, with a bearish technical signal and deep discount to book value (P/B 0.39). The company reported negative revenue and net income for 2025, though quarterly EPS has beaten estimates. It maintains a high dividend yield, paying $0.04 monthly, but faces net cash outflow and portfolio contraction concerns highlighted in recent news.
Outlook remains cautious due to financial deterioration and NAV erosion risks, offset by high yield and valuation discount. Analyst consensus is mixed with 25% buy ratings, reflecting divided opinion on recovery potential versus ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
